Ulinastatin-Based Immunomodulatory Strategies in Acute Lung Injury and Sepsis

Ulinastatin, a broad-spectrum urinary trypsin inhibitor, has emerged as a promising adjunct in the management of acute lung injury (ALI) and sepsis. By modulating protease activity and attenuating exaggerated inflammatory cascades, ulinastatin protects endothelial and epithelial barriers, mitigates cytokine-driven tissue damage, and promotes resolution of systemic inflammatory responses. Preclinical models have demonstrated that ulinastatin preserves pulmonary tight junction integrity, reduces neutrophil infiltration, and limits oxidative stress in the injured lung. In patients with sepsis, ulinastatin administration is associated with lower organ dysfunction scores, improved oxygenation indices, and reduced incidence of multiple organ dysfunction syndrome. Mechanistically, ulinastatin down-regulates key pro-inflammatory mediators such as tumour necrosis factor-α and interleukin-6, inhibits nuclear factor-κB and mitogen-activated protein kinase pathways, and fosters the release of anti-inflammatory cytokines. These multifaceted effects underpin its ability to restore immune homeostasis, decrease capillary leakage, and ultimately improve clinical outcomes in critically ill cohorts.

Research from Nature Portfolio

Recent observational analyses have firmed the case for ulinastatin in sepsis management. A large retrospective cohort study evaluated the impact of adjunctive ulinastatin on 28-day mortality in critically ill septic patients. Use of ulinastatin was linked to a substantial reduction in mortality risk, with mediation analysis indicating that suppression of acute-phase reactants—principally C-reactive protein—accounted for over one-third of the observed survival benefit. Economic evaluation within the same cohort showed higher drug and total hospital costs in the ulinastatin group, yet adjusted models preserved the mortality advantage. This work underscores both the immunomodulatory power of ulinastatin and the importance of balancing therapeutic gains against resource implications in intensive care settings.

Ulinastatin-Based Immunomodulatory Strategies in Acute Lung Injury and Sepsis publication trend

The graph below shows the total number of articles in ulinastatin-based immunomodulatory strategies in acute lung injury and sepsis across all publications each year (not limited to Nature Index journals).

Technical terms

Ulinastatin: A urinary trypsin inhibitor that suppresses serine proteases and inflammatory mediators.

Acute lung injury (ALI): Rapid-onset pulmonary inflammation characterised by increased vascular permeability and hypoxaemia.

Sepsis: Life-threatening organ dysfunction caused by a dysregulated host response to infection.

Immunomodulation: Adjustment of immune responses through therapeutic agents to restore homeostasis.

Tight junctions: Protein complexes between endothelial or epithelial cells that regulate paracellular permeability.

Cytokines: Small proteins released by cells that mediate and regulate immunity, inflammation and haematopoiesis.

References

1. Improvement of Sepsis Prognosis by Ulinastatin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacology (2019).
2. Ulinastatin Ameliorates Pulmonary Capillary Endothelial Permeability Induced by Sepsis Through Protection of Tight Junctions via Inhibition of TNF-α and Related Pathways. Frontiers in Pharmacology (2018).
3. Combination therapy of Ulinastatin with Thrombomodulin alleviates endotoxin (LPS) - induced liver and kidney injury via inhibiting apoptosis, oxidative stress and HMGB1/TLR4/NF-κB pathway. Bioengineered (2022).
4. Evaluation of the Pharmacological Function of Ulinastatin in Experimental Animals. Molecules (2012).
5. Ulinastatin is effective in reducing mortality for critically ill patients with sepsis: a causal mediation analysis. Scientific Reports (2018).